Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use. #ozempic #weightloss #health #fda
Chronic kidney disease is a common complication of type 2 diabetes and affects more than 35.5 million US adults, according to the Centers for Disease Control and Prevention. The approval from the Food and Drug Administration is the latest example of how Ozempic and other drugs like it, called GLP-1s, are being used to treat diabetes-related conditions, such as heart disease.
Expanding the use of Novo’s semaglutide — branded as Ozempic for diabetes and Wegovy for weight loss — is a crucial part of the Danish drugmaker’s efforts to boost access and sales.
Shares of Novo opened up about 1% in early trading Wednesday. The stock is down 18% in the past 12 months through Tuesday’s close.
Read more:
——–
Subscribe to our YouTube channel:
Subscribe to Bloomberg Originals:
Bloomberg Quicktake brings you global social video spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.
Connect with us on…
YouTube:
Breaking News on YouTube:
source
